Axcella Health (NASDAQ:AXLA) posted its earnings results on Monday. The company reported ($0.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.31), Bloomberg Earnings reports.

Shares of Axcella Health stock opened at $7.68 on Wednesday. The stock’s fifty day simple moving average is $8.19. Axcella Health has a 12 month low of $6.10 and a 12 month high of $15.99.

In other news, Director David R. Epstein bought 14,500 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was acquired at an average cost of $9.57 per share, with a total value of $138,765.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David R. Epstein bought 5,500 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was purchased at an average cost of $10.02 per share, with a total value of $55,110.00. The disclosure for this purchase can be found here. Insiders have purchased 38,293 shares of company stock worth $337,682 over the last quarter.

A number of research analysts have recently weighed in on the company. Leerink Swann assumed coverage on Axcella Health in a report on Monday, June 3rd. They issued an “outperform” rating on the stock. Zacks Investment Research lowered Axcella Health from a “hold” rating to a “sell” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. began coverage on Axcella Health in a report on Monday, June 3rd. They set an “overweight” rating and a $20.00 price target on the stock. Svb Leerink began coverage on Axcella Health in a report on Monday, June 3rd. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Goldman Sachs Group began coverage on Axcella Health in a report on Sunday, June 2nd. They set a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $22.00.

Axcella Health Company Profile

There is no company description available for Axcella Health Inc

Read More: Golden Cross

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.